Sellas Life Sciences Group Gets FDA Orphan Drug Designation to Treat Type of Leukemia

By Sabela Ojea

Sellas Life Sciences Group said it received an orphan drug designation from the U.S. Food and Drug Administration to treat acute myeloid leukemia.

The clinical biopharmaceutical company on Tuesday said its SLS009 inhibator, aimed at being administered twice weekly, has shown a favorable safety profile, strong initial efficacy signals and evidence of antitumor activity.

Orphan drug designations are granted to drugs or biologics used for the treatment, prevention or diagnosis of a rare disease that affects less than 200,000 people in the U.S.

Write to Sabela Ojea at [e-mail]; @sabelaojeaguix

(END) Dow Jones Newswires

10-10-23 1647ET